Symberix - Multiple Adjunct and Monotherapeutic Indications Drug
From Pipeline
Symberix is advancing a portfolio of first-in-class drug candidates for multiple adjunct and monotherapeutic indications. Our discovery platform enables precise targeting of bacteria implicated in intestinal toxicity and gastrointestinal disease. By identifying specific bacterial enzyme targets, we can develop small molecule drugs to block harmful bacterial activity without disrupting the innocuous endogenous microbiota.
-
Most popular related searches
Customer reviews
No reviews were found for Symberix - Multiple Adjunct and Monotherapeutic Indications Drug. Be the first to review!